Farmaspal (Syrup) Instructions for Use
Marketing Authorization Holder
Irvin 2, LLC (Russia)
Manufactured By
Pharmera LLC (Russia)
ATC Code
R03DX03 (Fenspiride)
Active Substance
Fenspiride (Rec.INN registered by WHO)
Dosage Form
| Farmaspal | Syrup 2 mg/ml: 150 ml bottle |
Dosage Form, Packaging, and Composition
Syrup in the form of a colorless or slightly yellowish transparent liquid.
| 1 ml | |
| Fenspiride hydrochloride | 2 mg |
Excipients: glycerol – 225 mg, methylparahydroxybenzoate – 0.9 mg, propylparahydroxybenzoate – 0.35 mg, sodium saccharin – 0.45 mg, sucrose – 600 mg, potassium sorbate – 1.9 mg, citric acid monohydrate – up to 0.2 mg, purified water – up to 1 ml.
150 ml – brown glass bottles (1) – cardboard packs.
Clinical-Pharmacological Group
Anti-inflammatory, anti-bronchoconstrictor agent
Pharmacotherapeutic Group
Anti-inflammatory anti-bronchoconstrictor agent
Pharmacological Action
An agent with bronchodilator and anti-inflammatory action. Reduces the manifestations of bronchospasm and inflammation in the airways. The mechanism of action is associated with antagonistic activity against histamine H1-receptors and with myotropic antispasmodic activity.
Reduces the production of a number of biologically active substances involved in the development of inflammation and contributing to increased bronchial tone (including cytokines, TNFα, arachidonic acid derivatives, free radicals).
Pharmacokinetics
Well absorbed from the gastrointestinal tract. Cmax is reached 6 hours after administration and decreases 3-fold after 12 hours.
Excreted primarily by the kidneys (90%), through the intestines – 10%. T1/2 – 12 hours.
Indications
Rhinopharyngitis, laryngitis, otitis, sinusitis, rhinotracheobronchitis, bronchitis, maintenance therapy for isolated and complicated bronchial asthma, respiratory symptoms in measles, whooping cough, influenza; infectious diseases of the respiratory tract accompanied by cough, when standard antibiotic therapy is indicated.
ICD codes
| ICD-10 code | Indication |
| A37 | Whooping cough |
| B05 | Measles |
| H66 | Suppurative and unspecified otitis media |
| J00 | Acute nasopharyngitis (common cold) |
| J01 | Acute sinusitis |
| J02 | Acute pharyngitis |
| J04 | Acute laryngitis and tracheitis |
| J06.9 | Acute upper respiratory infection, unspecified |
| J10 | Influenza due to identified seasonal influenza virus |
| J20 | Acute bronchitis |
| J31.0 | Chronic rhinitis (including ozaena, atrophic and hypertrophic rhinitis) |
| J31.2 | Chronic pharyngitis |
| J32 | Chronic sinusitis |
| J37 | Chronic laryngitis and laryngotracheitis |
| J42 | Unspecified chronic bronchitis |
| J45 | Asthma |
| R05 | Cough |
| ICD-11 code | Indication |
| 1C12.Z | Whooping cough, unspecified |
| 1E30 | Influenza due to identified seasonal influenza virus |
| 1F03 | Measles |
| AA9Z | Unspecified suppurative otitis media |
| CA00 | Acute nasopharyngitis |
| CA01 | Acute rhinosinusitis |
| CA02.Z | Acute pharyngitis, unspecified |
| CA05 | Acute laryngitis or tracheitis |
| CA07.0 | Acute upper respiratory tract infection of unspecified site |
| CA09.0 | Chronic rhinitis |
| CA09.2 | Chronic pharyngitis |
| CA0A.Z | Chronic rhinosinusitis, unspecified |
| CA0G | Chronic laryngitis or laryngotracheitis |
| CA20.1Z | Chronic bronchitis, unspecified |
| CA23 | Asthma |
| CA42.Z | Acute bronchitis, unspecified |
| MD12 | Cough |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Take orally before meals.
For adults, administer 80 mg two to three times daily.
For children over 2 years of age, calculate the dose at 4 mg per kg of body weight per day.
Divide the total daily dose for children into two or three separate administrations.
Use the provided measuring cup for accurate dosing; do not use household spoons.
Shake the bottle well before each use.
The maximum daily dose for adults is 240 mg.
Adhere strictly to the prescribed dosing frequency and duration of treatment.
Do not exceed the recommended dosage.
Adverse Reactions
From the cardiovascular system rarely – tachycardia, the severity of which decreases with dose reduction; frequency unknown – palpitations, decreased blood pressure, possibly associated with tachycardia.
From the digestive system often – dyspeptic symptoms, nausea, epigastric pain; frequency unknown – diarrhea, vomiting.
From the nervous system rarely – drowsiness; frequency unknown – dizziness.
From the skin and subcutaneous tissues: rarely – erythema, rash, urticaria, angioedema, fixed pigmentary erythema; frequency unknown – skin itching, toxic epidermal necrolysis, Stevens-Johnson syndrome.
Other: frequency unknown: asthenia – increased fatigue.
Contraindications
Hypersensitivity to fenspiride; pregnancy, lactation (breastfeeding); childhood – depending on the dosage form.
With caution
Concomitant use of sedative drugs.
Use in Pregnancy and Lactation
Fenspiride is contraindicated for use during pregnancy and lactation (breastfeeding).
Pediatric Use
Can be used in children according to indications, in age-appropriate recommended doses and dosage forms. It is necessary to strictly follow the instructions in the fenspiride drug leaflets regarding contraindications for the use of specific fenspiride dosage forms in children of different ages.
Special Precautions
Treatment with fenspiride does not replace antibacterial therapy and should not be a reason to delay the adequate prescription of antibacterial drugs.
Fenspiride should be used with caution simultaneously with sedative drugs.
Effect on the ability to drive vehicles and machinery
During the use of fenspiride, patients should exercise caution when driving vehicles and machinery, as well as when engaging in other potentially hazardous activities that require increased concentration and speed of psychomotor reactions.
Drug Interactions
When using fenspiride in combination with drugs that have a sedative effect or together with alcohol, an enhancement of the sedative effect is possible.
Storage Conditions
Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Rx Only
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer